Immunic, Inc. (NASDAQ:IMUX) Given Average Rating of “Buy” by Analysts

Immunic, Inc. (NASDAQ:IMUX) has been assigned a consensus recommendation of “Buy” from the eight research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $7.40.

A number of analysts have recently weighed in on IMUX shares. HC Wainwright reduced their price target on shares of Immunic from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, November 14th. Weiss Ratings restated a “sell (e+)” rating on shares of Immunic in a research report on Monday. D. Boral Capital decreased their price target on Immunic from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, November 13th. Chardan Capital raised Immunic to a “strong-buy” rating in a research note on Wednesday, November 19th. Finally, Roth Capital assumed coverage on Immunic in a report on Friday, November 7th. They issued a “buy” rating and a $3.00 price objective for the company.

Hedge Funds Weigh In On Immunic

Several large investors have recently made changes to their positions in IMUX. Qube Research & Technologies Ltd acquired a new position in shares of Immunic in the 3rd quarter worth approximately $29,000. Millennium Management LLC boosted its holdings in Immunic by 414.5% during the third quarter. Millennium Management LLC now owns 530,470 shares of the company’s stock worth $468,000 after buying an additional 427,361 shares in the last quarter. Focus Partners Wealth grew its position in Immunic by 1.5% in the third quarter. Focus Partners Wealth now owns 2,581,587 shares of the company’s stock worth $2,276,000 after buying an additional 39,063 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Immunic in the third quarter valued at $99,000. Finally, Two Sigma Investments LP acquired a new stake in shares of Immunic during the 3rd quarter valued at $52,000. Institutional investors own 51.82% of the company’s stock.

Immunic Stock Performance

Shares of IMUX opened at $0.62 on Friday. Immunic has a one year low of $0.56 and a one year high of $1.39. The stock’s fifty day moving average is $0.76 and its 200-day moving average is $0.82. The firm has a market capitalization of $74.76 million, a price-to-earnings ratio of -0.75 and a beta of 1.48.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.05. Analysts forecast that Immunic will post -0.94 EPS for the current fiscal year.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.